Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
Selective BRM inhibition has been a sought-after objective in cancer research for many years.
- Selective BRM inhibition has been a sought-after objective in cancer research for many years.
- A variety of tumor types, including NSCLC, are known to have mutations in BRG1, which we believe make them dependent on BRM activity for their survival.
- Selective blocking of BRM activity is considered a promising strategy for causing tumor cell death while sparing healthy cells.
- The collaboration includes a US 50/50 co-development and co-commercialization agreement for Foghorn’s Selective BRM oncology program and an additional undisclosed oncology target.